266 related articles for article (PubMed ID: 37540258)
1. [Transthyretin amyloid cardiomyopathy].
Czepluch F
Inn Med (Heidelb); 2023 Sep; 64(9):823-829. PubMed ID: 37540258
[TBL] [Abstract][Full Text] [Related]
2.
Tahara N; Lairez O; Endo J; Okada A; Ueda M; Ishii T; Kitano Y; Lee HE; Russo E; Kubo T
ESC Heart Fail; 2022 Feb; 9(1):251-262. PubMed ID: 34841715
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States.
Lau ATC; DiDomenico RJ; Kim K
Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
[TBL] [Abstract][Full Text] [Related]
6. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: red-flag symptom clusters and diagnostic algorithm.
Inomata T; Tahara N; Nakamura K; Endo J; Ueda M; Ishii T; Kitano Y; Koyama J
ESC Heart Fail; 2021 Aug; 8(4):2647-2659. PubMed ID: 34137515
[TBL] [Abstract][Full Text] [Related]
8. Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications.
Tini G; Sessarego E; Benenati S; Vianello PF; Musumeci B; Autore C; Canepa M
Eur J Clin Invest; 2021 Dec; 51(12):e13665. PubMed ID: 34390490
[TBL] [Abstract][Full Text] [Related]
9. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P
JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046
[TBL] [Abstract][Full Text] [Related]
10. Hereditary cardiac amyloidosis associated with Pro24Ser transthyretin mutation: a case report.
Yamamoto H; Hashimoto T; Kawamura S; Hiroe M; Yamashita T; Ando Y; Yokochi T
J Med Case Rep; 2018 Dec; 12(1):370. PubMed ID: 30553273
[TBL] [Abstract][Full Text] [Related]
11. Exploring Transthyretin Amyloid Cardiomyopathy: A Comprehensive Review of the Disease and Upcoming Treatments.
Jain H; Reddy MMRK; Dey RC; Jain J; Shakhatreh Z; Manandhar S; Neupane P; Waleed MS; Yadav R; Sah BK; Mahawa R
Curr Probl Cardiol; 2024 Jan; 49(1 Pt B):102057. PubMed ID: 37640179
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction.
AbouEzzeddine OF; Davies DR; Scott CG; Fayyaz AU; Askew JW; McKie PM; Noseworthy PA; Johnson GB; Dunlay SM; Borlaug BA; Chareonthaitawee P; Roger VL; Dispenzieri A; Grogan M; Redfield MM
JAMA Cardiol; 2021 Nov; 6(11):1267-1274. PubMed ID: 34431962
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cardiac transthyretin amyloidosis: an update.
Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
15. Detection of transthyretin amyloid cardiomyopathy by automated data extraction from electronic health records.
Moya A; Oeste CL; Beles M; Verstreken S; Dierckx R; Heggermont W; Bartunek J; Bogaerts E; Masuy I; Hens D; Bertolone D; Vanderheyden M
ESC Heart Fail; 2023 Dec; 10(6):3483-3492. PubMed ID: 37726928
[TBL] [Abstract][Full Text] [Related]
16. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
17. Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis.
Bistola V; Parissis J; Foukarakis E; Valsamaki PN; Anastasakis A; Koutsis G; Efthimiadis G; Kastritis E
Heart Fail Rev; 2021 Jul; 26(4):861-879. PubMed ID: 33452596
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and biophysical properties of a rare TTRA81V mutation causing mild transthyretin amyloid cardiomyopathy.
Sha Q; Zhang Y; Wang M; Sun J; Zhang Y; Zhang X; Wang N; Liu Y; Liu Y
ESC Heart Fail; 2024 Feb; 11(1):112-125. PubMed ID: 37827496
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies.
Yadav JD; Othee H; Chan KA; Man DC; Belliveau PP; Towle J
Ann Pharmacother; 2021 Dec; 55(12):1502-1514. PubMed ID: 33685242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
